The data showed that the PARK2 gene significantly inhibited tumor growth in vivo (Fig. 4a); at the end of the experiment, the tumor sizes were 1238 ± 121.8 mm3 vs. 1,905 ± 390.8 mm3 and the tumor weights were 1.552 ± 0.088 g vs. 2.058 ± 0.201 g in the PARK2 and NC groups, respectively (P < 0.05, Fig. 4b, c). The gene discussed is PRKN; the disease is neoplasm.